The Global Health Body Raises Alert Over Acute Lack of Obesity Injections
Less than one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it issues its initial recommendations on the drugs.
Considering over a billion people worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant obstacles to broad access to the treatments that can aid individuals in losing substantial body mass, says the organization.
Skinny Jab Supply Crisis
Even under the present most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, per the WHO.
The advice calls on nations and manufacturers to increase availability, through approaches including licensing agreements.
Exclusive production rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
How Obesity Drugs Operate
These medications mimick a biological compound to delay gastric emptying, reduce hunger and increase satiety so individuals eat less.
Individuals usually begin shedding pounds within a few weeks of beginning the weekly injections.
Evidence points to users may regain a significant portion within a year of stopping the treatment, as their usual food cravings return.
To be carrying excess weight elevates your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.
Obesity impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
